Abstract
Purpose
Lacosamide (LCM) is an effective antiepileptic drug (AED) approved for the treatment of focal epilepsy in both children and adults. The aim of this observational study was to review our centre’s experience with LCM and to characterise its efficacy and tolerability as an adjunct therapy in children with refractory focal epilepsy.
Methods
We retrospectively reviewed the medical records of 12 paediatric patients who underwent treatment with LCM from January 2014 to December 2015. We recorded the treatment response at three time points: at 3 and 6 months after LCM therapy and at the final follow-up visit. Children showing seizure reduction ≥ 50% were considered responders.
Results
We included 12 patients (five boys), and their mean age was 13.8 years (range: 6.2–17.6 years) at the end of LCM treatment. The average length of follow-up after starting LCM was 23 months (11–37 months). Eight patients (66%) had > 50% reduction in seizures at the 3-month follow-up visit, and seven (58%) had > 50% reduction at the 6-month follow-up visit. Six patients (50%) maintained ≥ 50% reduction in seizures at the final follow-up visit. Two patients (16.6%) were seizure free at the 6-month and final follow-up visits. Common adverse side effects included dizziness, ataxia, nausea, and vomiting. Two patients developed status epilepticus (SE), one each at 3 and 11 days after the first LCM dose; they both discontinued treatment.
Conclusions
Our study points to the efficacy of LCM in a small paediatric group. Furthermore, it was important to report status epilepticus after LCM administration in the paediatric population for the first time.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342:314–319
Casas-Fernández C, Martínez-Bermejo A, Rufo-Campos M, Smeyers-Durá P, Herranz-Fernández JL, Ibáñez-Micó S et al (2012) Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: a prospective, open-label, observational, multicenter study in Spain. Drugs R D 12(4):187–197
Doty P, Hebert D, Mathy FX, Byrnes W, Zackheim J, Simontac- chi K (2013) Development of lacosamide for the treatment of partial-onset seizures. Ann N Y Acad Sci 1291:56–68
Guilhoto LM, Loddenkemper T, Gooty VD, Rotenberg A, Takeoka M, Duffy FH et al (2011) Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr Neurol 44(6):414–419
Gavatha M, Ioannou I, Papavasiliou AS (2011) Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy. Epilepsy Behav 20(4):691–693
Heyman E, Lahat E, Levin N, Berkovitch M, Gandelman-Marton R (2012) Preliminary efficacy and safety of lacosamide in children with refractory epilepsy. Eur J Paediatr Neurol 16(1):15–19
Grosso S, Parisi P, Spalice A, Verrotti A, Balestri P (2014) Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy. Eur J Paediatr Neurol 18(1):55–59
Kim JS, Kim H, Lim BC, Chae JH, Choi J, Kim KJ et al (2014) Lacosamide as an adjunctive therapy in pediatric patients with refractory focal epilepsy. Brain and Development 36(6):510–515
Pasha I, Kamate M, Didagi SK (2014) Efficacy and tolerability of lacosamide as an adjunctive therapy in children with refractory partial epilepsy. Pediatr Neurol 51(4):509–514
Yorns WR Jr, Khurana DS, Carvalho KS, Hardison HH, Legido A, Valencia I. (2014) Efficacy of lacosamide as adjunctive therapy in children with refractory epilepsy. J Child Neurol 29(1): 23–27
Verrotti A, Loiacono G, Pizzolorusso A, Parisi P, Bruni O, Luchetti A et al (2013) Lacosamide in pediatric and adult patients: comparison of efficacy and safety. Seizure 22(3):210–216
Rastogi RG, Ng YT (2012) Lacosamide in refractory mixed pediatric epilepsy: a prospective add-on study. J Child Neurol 27(4):492–495
Toupin JF, Lortie A, Major P, Diadori P, Vanasse M, Rossignol E et al (2015) Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre study. Epileptic Disord 17(4):436–443
Villanueva V, Lopez-Gomariz E, Lopez-Trigo J, Palau J, García M, Villarroya T et al (2012) Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA. Epilepsy Behav 23(3):298–304
Buck ML, Goodkin HP (2012) Use of lacosamide in children with refractory epilepsy. J Pediatr Pharmacol Ther 17:211–219
Papacostas SS (2015) Status epilepticus developing during lacosamide monotherapy. BMJ Case Rep 2015
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Yildiz, E.P., Ozkan, M.U., Bektas, G. et al. Lacosamide treatment of childhood refractory focal epilepsy: the first reported side effect in paediatric patients. Childs Nerv Syst 33, 2023–2027 (2017). https://doi.org/10.1007/s00381-017-3586-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00381-017-3586-8